Download PDF
Digestive Disease Interventions 2019; 03(04): 305-313
DOI: 10.1055/s-0039-1697652
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Medical Management after Liver Transplantation

Shravan Dave 
1   Division of Gastroenterology, Department of Medicine, University of California – San Diego, La Jolla, California
,
Veeral H. Ajmera 
1   Division of Gastroenterology, Department of Medicine, University of California – San Diego, La Jolla, California
› Author Affiliations Fundings VA is supported by the AASLD Foundation Clinical and Translational Research Award.
Further Information

Publication History

27 February 2019

07 August 2019

Publication Date:
07 October 2019 (online)

Also available at
    Permissions and Reprints

Abstract

Medical management of the liver transplant recipient requires consideration of the complex interactions between the transplanted liver, immunosuppression and all organ systems. An aging transplant population, improvement in long-term liver transplant outcomes, and the increase in nonalcoholic fatty liver disease as an indication for transplant have amplified the number of co-morbidities among post-transplant patients. In addition to balancing immunosuppression with infection risk, medical management of the transplanted patient includes monitoring for, and treating, recurrence of the primary liver disease, metabolic syndrome, cardiovascular disease, and post-transplant neurologic and renal dysfunction. Additionally, general healthcare maintenance such as management of osteoporosis, immunizations, and screening for malignancy are essential in this high-risk population. In this review, we summarize the evidence behind best practices for the current medical management of the post liver transplant patient.

Keywords

post-liver transplant - immunosuppression - graft loss

Author Contributions

Shravan Dave: drafting of the manuscript, critical revision of the manuscript, approved final submission.


Veeral Ajmera: drafting of the manuscript, critical revision of the manuscript, approved final submission.


 

  • References

  • 1 Kim WR, Lake JR, Smith JM. , et al. OPTN/SRTR 2016 Annual data report: Liver. Am J Transplant 2018; 18 (Suppl. 01) 172-253
    CrossrefPubMedGoogle Scholar
  • 2 Moini M, Schilsky ML, Tichy EM. Review on immunosuppression in liver transplantation. World J Hepatol 2015; 7 (10) 1355-1368
    CrossrefPubMedGoogle Scholar
  • 3 Taner T, Heimbach JK, Rosen CB, Nyberg SL, Park WD, Stegall MD. Decreased chronic cellular and antibody-mediated injury in the kidney following simultaneous liver-kidney transplantation. Kidney Int 2016; 89 (04) 909-917
    CrossrefPubMedGoogle Scholar
  • 4 Starzl TE, Marchioro TL, Vonkaulla KN, Hermann G, Brittain RS, Waddell WR. Homotransplantation of the liver in humans. Surg Gynecol Obstet 1963; 117: 659-676
    PubMedGoogle Scholar
  • 5 Levitsky J, Feng S. Tolerance in clinical liver transplantation. Hum Immunol 2018; 79 (05) 283-287
    CrossrefPubMedGoogle Scholar
  • 6 Coutinho AE, Chapman KE. The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights. Mol Cell Endocrinol 2011; 335 (01) 2-13
    CrossrefPubMedGoogle Scholar
  • 7 Mukherjee S, Mukherjee U. A comprehensive review of immunosuppression used for liver transplantation. J Transplant 2009; 2009: 701464-701464
    PubMedGoogle Scholar
  • 8 O'Grady JG, Burroughs A, Hardy P, Elbourne D, Truesdale A. ; UK and Republic of Ireland Liver Transplant Study Group. Tacrolimus versus microemulsified ciclosporin in liver transplantation: the TMC randomised controlled trial. Lancet 2002; 360 (9340): 1119-1125
    CrossrefPubMedGoogle Scholar
  • 9 O'Grady JG, Hardy P, Burroughs AK, Elbourne D. ; UK and Ireland Liver Transplant Study Group. Randomized controlled trial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: poststudy surveillance to 3 years. Am J Transplant 2007; 7 (01) 137-141
    CrossrefPubMedGoogle Scholar
  • 10 Boillot O, Seket B, Dumortier J. , et al. Thymoglobulin induction in liver transplant recipients with a tacrolimus, mycophenolate mofetil, and steroid immunosuppressive regimen: a five-year randomized prospective study. Liver Transpl 2009; 15 (11) 1426-1434
    CrossrefPubMedGoogle Scholar
  • 11 Goralczyk AD, Hauke N, Bari N, Tsui TY, Lorf T, Obed A. Interleukin 2 receptor antagonists for liver transplant recipients: a systematic review and meta-analysis of controlled studies. Hepatology 2011; 54 (02) 541-554
    CrossrefPubMedGoogle Scholar
  • 12 Geissler EK, Schnitzbauer AA, Zülke C. , et al. Sirolimus use in liver transplant recipients with hepatocellular carcinoma: a randomized, multicenter, open-label phase 3 trial. Transplantation 2016; 100 (01) 116-125
    CrossrefPubMedGoogle Scholar
  • 13 Baganate F, Beal EW, Tumin D. , et al. Early mortality after liver transplantation: defining the course and the cause. Surgery 2018; 164 (04) 694-704
    CrossrefPubMedGoogle Scholar
  • 14 Lucey MR, Terrault N, Ojo L. , et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl 2013; 19 (01) 3-26
    CrossrefPubMedGoogle Scholar
  • 15 Koval C. Echinocandins for antifungal prophylaxis in liver transplant recipients: Advance in the field or variation on a theme?. Liver Transpl 2016; 22 (04) 396-398
    CrossrefPubMedGoogle Scholar
  • 16 Banff schema for grading liver allograft rejection: an international consensus document. Hepatology 1997; 25 (03) 658-663
    CrossrefPubMedGoogle Scholar
  • 17 Thurairajah PH, Carbone M, Bridgestock H. , et al. Late acute liver allograft rejection; a study of its natural history and graft survival in the current era. Transplantation 2013; 95 (07) 955-959
    CrossrefPubMedGoogle Scholar
  • 18 Uemura T, Ikegami T, Sanchez EQ. , et al. Late acute rejection after liver transplantation impacts patient survival. Clin Transplant 2008; 22 (03) 316-323
    CrossrefPubMedGoogle Scholar
  • 19 Levitsky J, Goldberg D, Smith AR. , et al. Acute rejection increases risk of graft failure and death in recent liver transplant recipients. Clin Gastroenterol Hepatol 2017; 15 (04) 584-593.e2
    CrossrefPubMedGoogle Scholar
  • 20 Demetris AJ, Adeyi O, Bellamy CO. , et al; Banff Working Group. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology 2006; 44 (02) 489-501
    CrossrefPubMedGoogle Scholar
  • 21 Wiesner RH, Batts KP, Krom RAF. Evolving concepts in the diagnosis, pathogenesis, and treatment of chronic hepatic allograft rejection. Liver Transpl Surg 1999; 5 (05) 388-400
    CrossrefPubMedGoogle Scholar
  • 22 Mazzaferro V, Regalia E, Doci R. , et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334 (11) 693-699
    CrossrefPubMedGoogle Scholar
  • 23 Yao FY, Ferrell L, Bass NM, Bacchetti P, Ascher NL, Roberts JP. Liver transplantation for hepatocellular carcinoma: comparison of the proposed UCSF criteria with the Milan criteria and the Pittsburgh modified TNM criteria. Liver Transpl 2002; 8 (09) 765-774
    CrossrefPubMedGoogle Scholar
  • 24 Agopian VG, Harlander-Locke M, Zarrinpar A. , et al. A novel prognostic nomogram accurately predicts hepatocellular carcinoma recurrence after liver transplantation: analysis of 865 consecutive liver transplant recipients. J Am Coll Surg 2015; 220 (04) 416-427
    CrossrefPubMedGoogle Scholar
  • 25 Halazun KJ, Najjar M, Abdelmessih RM. , et al. Recurrence after liver transplantation for hepatocellular carcinoma: a new MORAL to the story. Ann Surg 2017; 265 (03) 557-564
    CrossrefPubMedGoogle Scholar
  • 26 Mehta N, Heimbach J, Harnois DM. , et al. Validation of a risk estimation of tumor recurrence after transplant (RETREAT) score for hepatocellular carcinoma recurrence after liver transplant. JAMA Oncol 2017; 3 (04) 493-500
    CrossrefPubMedGoogle Scholar
  • 27 Kulik L, Vouche M, Koppe S. , et al. Prospective randomized pilot study of Y90+/−sorafenib as bridge to transplantation in hepatocellular carcinoma. J Hepatol 2014; 61 (02) 309-317
    CrossrefPubMedGoogle Scholar
  • 28 Truesdale AE, Caldwell SH, Shah NL. , et al. Sorafenib therapy for hepatocellular carcinoma prior to liver transplant is associated with increased complications after transplant. Transpl Int 2011; 24 (10) 991-998
    CrossrefPubMedGoogle Scholar
  • 29 Gassmann D, Weiler S, Mertens JC. , et al. Liver allograft failure after nivolumab treatment-a case report with systematic literature research. Transplant Direct 2018; 4 (08) e376
    CrossrefPubMedGoogle Scholar
  • 30 Garcia-Retortillo M, Forns X, Feliu A. , et al. Hepatitis C virus kinetics during and immediately after liver transplantation. Hepatology 2002; 35 (03) 680-687
    CrossrefPubMedGoogle Scholar
  • 31 Jiménez-Pérez M, González-Grande R, Rando-Muñoz FJ. Management of recurrent hepatitis C virus after liver transplantation. World J Gastroenterol 2014; 20 (44) 16409-16417
    CrossrefPubMedGoogle Scholar
  • 32 Levitsky J, Verna EC, O'Leary JG. , et al. Perioperative ledipasvir-sofosbuvir for HCV in liver-transplant recipients. N Engl J Med 2016; 375 (21) 2106-2108
    CrossrefPubMedGoogle Scholar
  • 33 Liapakis A, Formica RN, Levitsky J. Solid organ transplantation of viral hepatitis C positive donor organs into viral hepatitis C negative recipients. Curr Opin Organ Transplant 2018; 23 (02) 257-263
    CrossrefPubMedGoogle Scholar
  • 34 Burra P, Germani G, Adam R. , et al. Liver transplantation for HBV-related cirrhosis in Europe: an ELTR study on evolution and outcomes. J Hepatol 2013; 58 (02) 287-296
    CrossrefPubMedGoogle Scholar
  • 35 Radhakrishnan K, Chi A, Quan DJ, Roberts JP, Terrault NA. Short course of postoperative hepatitis B immunoglobulin plus antivirals prevents reinfection of liver transplant recipients. Transplantation 2017; 101 (09) 2079-2082
    CrossrefPubMedGoogle Scholar
  • 36 Fung J, Wong T, Chok K. , et al. Long-term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: Results up to 8 years. Hepatology 2017; 66 (04) 1036-1044
    CrossrefPubMedGoogle Scholar
  • 37 Terrault NA, Lok ASF, McMahon BJ. , et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018; 67 (04) 1560-1599
    CrossrefPubMedGoogle Scholar
  • 38 Ilyas JA, O'Mahony CA, Vierling JM. Liver transplantation in autoimmune liver diseases. Best Pract Res Clin Gastroenterol 2011; 25 (06) 765-782
    CrossrefPubMedGoogle Scholar
  • 39 Carbone M, Neuberger JM. Autoimmune liver disease, autoimmunity and liver transplantation. J Hepatol 2014; 60 (01) 210-223
    CrossrefPubMedGoogle Scholar
  • 40 Kalra A, Burton Jr JR, Forman LM. Pro: steroids can be withdrawn after transplant in recipients with autoimmune hepatitis. Liver Transpl 2018; 24 (08) 1109-1112
    CrossrefPubMedGoogle Scholar
  • 41 Prados E, Cuervas-Mons V, de la Mata M. , et al. Outcome of autoimmune hepatitis after liver transplantation. Transplantation 1998; 66 (12) 1645-1650
    CrossrefPubMedGoogle Scholar
  • 42 Bosch A, Dumortier J, Maucort-Boulch D. , et al. Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence. J Hepatol 2015; 63 (06) 1449-1458
    CrossrefPubMedGoogle Scholar
  • 43 Graziadei IW. Recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl 2002; 8 (07) 575-581
    CrossrefPubMedGoogle Scholar
  • 44 Lee BP, Vittinghoff E, Dodge JL, Cullaro G, Terrault NA. National trends and long-term outcomes of liver transplant for alcohol-associated liver disease in the United States. JAMA Intern Med 2019; 179 (03) 340-348
    CrossrefPubMedGoogle Scholar
  • 45 Mathurin P, Moreno C, Samuel D. , et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2011; 365 (19) 1790-1800
    CrossrefPubMedGoogle Scholar
  • 46 Lee BP, Mehta N, Platt L. , et al. Outcomes of early liver transplantation for patients with severe alcoholic hepatitis. Gastroenterology 2018; 155 (02) 422-430.e1
    CrossrefPubMedGoogle Scholar
  • 47 Lee BP, Vittinghoff E, Hsu C. , et al. Predicting low-risk for sustained alcohol use after early liver transplant for acute alcoholic hepatitis: the SALT score. Hepatology 2019; 69 (04) 1477-1487
    CrossrefPubMedGoogle Scholar
  • 48 DiMartini A, Dew MA, Day N. , et al. Trajectories of alcohol consumption following liver transplantation. Am J Transplant 2010; 10 (10) 2305-2312
    CrossrefPubMedGoogle Scholar
  • 49 Rice JP, Eickhoff J, Agni R, Ghufran A, Brahmbhatt R, Lucey MR. Abusive drinking after liver transplantation is associated with allograft loss and advanced allograft fibrosis. Liver Transpl 2013; 19 (12) 1377-1386
    CrossrefPubMedGoogle Scholar
  • 50 Narayanan P, Mara K, Izzy M. , et al. Recurrent or de novo allograft steatosis and long-term outcomes after liver transplantation. Transplantation 2019; 103 (01) e14-e21
    CrossrefPubMedGoogle Scholar
  • 51 Ekstedt M, Hagström H, Nasr P. , et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015; 61 (05) 1547-1554
    CrossrefPubMedGoogle Scholar
  • 52 Dahm F, Georgiev P, Clavien PA. Small-for-size syndrome after partial liver transplantation: definition, mechanisms of disease and clinical implications. Am J Transplant 2005; 5 (11) 2605-2610
    CrossrefPubMedGoogle Scholar
  • 53 Quintini C, D'Amico G, Brown C. , et al. Splenic artery embolization for the treatment of refractory ascites after liver transplantation. Liver Transpl 2011; 17 (06) 668-673
    CrossrefPubMedGoogle Scholar
  • 54 Xiao L, Li F, Wei B, Li B, Tang CW. Small-for-size syndrome after living donor liver transplantation: successful treatment with a transjugular intrahepatic portosystemic shunt. Liver Transpl 2012; 18 (09) 1118-1120
    CrossrefPubMedGoogle Scholar
  • 55 Sharma P, Welch K, Eikstadt R, Marrero JA, Fontana RJ, Lok AS. Renal outcomes after liver transplantation in the model for end-stage liver disease era. Liver Transpl 2009; 15 (09) 1142-1148
    CrossrefPubMedGoogle Scholar
  • 56 Levitsky J, O'Leary JG, Asrani S. , et al. Protecting the kidney in liver transplant recipients: practice-based recommendations from the American Society of Transplantation Liver and Intestine Community of Practice. Am J Transplant 2016; 16 (09) 2532-2544
    CrossrefPubMedGoogle Scholar
  • 57 De Simone P, Nevens F, De Carlis L. , et al; H2304 Study Group. Everolimus with reduced tacrolimus improves renal function in de novo liver transplant recipients: a randomized controlled trial. Am J Transplant 2012; 12 (11) 3008-3020
    CrossrefPubMedGoogle Scholar
  • 58 Teperman L, Moonka D, Sebastian A. , et al; Spare-the-Nephron Trial Liver Transplantation Study Group. Calcineurin inhibitor-free mycophenolate mofetil/sirolimus maintenance in liver transplantation: the randomized spare-the-nephron trial. Liver Transpl 2013; 19 (07) 675-689
    CrossrefPubMedGoogle Scholar
  • 59 Aǧıldere AM, Başaran C, Çakır B, Ozgül E, Kural F, Haberal M. Evaluation of neurologic complications by brain MRI in kidney and liver transplant recipients. Transplant Proc 2006; 38 (02) 611-618
    CrossrefPubMedGoogle Scholar
  • 60 Bronster DJ, Emre S, Boccagni P, Sheiner PA, Schwartz ME, Miller CM. Central nervous system complications in liver transplant recipients--incidence, timing, and long-term follow-up. Clin Transplant 2000; 14 (01) 1-7
    CrossrefPubMedGoogle Scholar
  • 61 Weiss N, Thabut D. Neurological complications occurring after liver transplantation: role of risk factors, hepatic encephalopathy, and acute (on chronic) brain injury. Liver Transpl 2019; 25 (03) 469-487
    CrossrefPubMedGoogle Scholar
  • 62 Ripoll C, Yotti R, Bermejo J, Bañares R. The heart in liver transplantation. J Hepatol 2011; 54 (04) 810-822
    CrossrefPubMedGoogle Scholar
  • 63 Albeldawi M, Aggarwal A, Madhwal S. , et al. Cumulative risk of cardiovascular events after orthotopic liver transplantation. Liver Transpl 2012; 18 (03) 370-375
    CrossrefPubMedGoogle Scholar
  • 64 VanWagner LB, Ning H, Whitsett M. , et al. A point-based prediction model for cardiovascular risk in orthotopic liver transplantation: The CAR-OLT score. Hepatology 2017; 66 (06) 1968-1979
    CrossrefPubMedGoogle Scholar
  • 65 Watt KDS, Pedersen RA, Kremers WK, Heimbach JK, Charlton MR. Evolution of causes and risk factors for mortality post-liver transplant: results of the NIDDK long-term follow-up study. Am J Transplant 2010; 10 (06) 1420-1427
    CrossrefPubMedGoogle Scholar
  • 66 Khurmi NS, Chang Y-H, Eric Steidley D. , et al. Hospitalizations for cardiovascular disease after liver transplantation in the United States. Liver Transpl 2018; 24 (10) 1398-1410
    CrossrefPubMedGoogle Scholar
  • 67 Vivarelli M, La Barba G, Cucchetti A. , et al. Can antiplatelet prophylaxis reduce the incidence of hepatic artery thrombosis after liver transplantation?. Liver Transpl 2007; 13 (05) 651-654
    CrossrefPubMedGoogle Scholar
  • 68 Guañabens N, Parés A. Osteoporosis in chronic liver disease. Liver Int 2018; 38 (05) 776-785
    CrossrefPubMedGoogle Scholar
  • 69 Collier J. Bone disorders in chronic liver disease. Hepatology 2007; 46 (04) 1271-1278
    CrossrefPubMedGoogle Scholar
  • 70 Chandok N, Watt KD. Burden of de novo malignancy in the liver transplant recipient. Liver Transpl 2012; 18 (11) 1277-1289
    CrossrefPubMedGoogle Scholar
  • 71 Burra P, Rodriguez-Castro KI. Neoplastic disease after liver transplantation: Focus on de novo neoplasms. World J Gastroenterol 2015; 21 (29) 8753-8768
    CrossrefPubMedGoogle Scholar
  • 72 Kamdar KY, Rooney CM, Heslop HE. Posttransplant lymphoproliferative disease following liver transplantation. Curr Opin Organ Transplant 2011; 16 (03) 274-280
    CrossrefPubMedGoogle Scholar
  • 73 Vink P, Ramon Torrell JM, Sanchez Fructuoso A. , et al; Z-041 study group. Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in chronically immunosuppressed adults following renal transplant: a phase III, randomized clinical trial. Clin Infect Dis 2019 ; doi: 10.1093/cid/ciz177
    PubMedGoogle Scholar